Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now? [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply by 15 to surpass $100 billion later this decade. Viking doesn't sell weight loss drugs yet, but it could be on the way. The biotech is studying injectable and oral formulations of VK2735 in clinical trials, and results so far have been impressive. As for stock performance, Viking won there too in the early part of last year. The stock surged 121% in one trading session about a year ago, right after Viking announced positive results from a VK2735 trial. In recent times, though, the stock has given up gains -- and this year, Viking has shed about 40%. But brighter days may be ahead, and this positive moment may have already started with a recent milestone. Viking completed enrollment of a phase 2 trial of its VK2735 oral candidate and says it expects to report results in the second half of this year. Considering this progress, is Viking a buy now? Let's find out. So before talkin
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk (NVO) Hit By Lowered Guidance [Yahoo! Finance]Yahoo! Finance
- 5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 [Yahoo! Finance]Yahoo! Finance
- BaseLaunch Announces the Addition of Takeda as New Pharmaceutical Partner to its Biotech Venture Incubator [Yahoo! Finance]Yahoo! Finance
- Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing [Yahoo! Finance]Yahoo! Finance
- These people lost their sense of taste. Are GLP-1s to blame? [USA TODAY]USA TODAY
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website